Astellas Pharma (OTCMKTS:ALPMY) Share Price Passes Below 50 Day Moving Average – Here’s Why

Astellas Pharma Inc. (OTCMKTS:ALPMY)’s share price crossed below its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $15.11 and traded as low as $15.03. Astellas Pharma shares last traded at $15.05, with a volume of 86,941 shares.

Analyst Ratings Changes

A number of research firms recently commented on ALPMY. Smbc Nikko Sec. raised shares of Astellas Pharma to a “hold” rating in a research note on Monday, February 16th. Citigroup downgraded shares of Astellas Pharma from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 19th. Four equities research analysts have rated the stock with a Hold rating, According to MarketBeat.com, Astellas Pharma currently has an average rating of “Hold”.

Astellas Pharma Trading Down 0.7%

The stock’s fifty day moving average price is $15.11 and its 200 day moving average price is $13.01. The company has a quick ratio of 0.84, a current ratio of 1.09 and a debt-to-equity ratio of 0.23.

Astellas Pharma (OTCMKTS:ALPMY) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $0.44 earnings per share for the quarter, beating analysts’ consensus estimates of $0.29 by $0.15. The company had revenue of $3.67 billion during the quarter, compared to analyst estimates of $3.21 billion. Astellas Pharma had a net margin of 15.63% and a return on equity of 23.62%. As a group, equities research analysts anticipate that Astellas Pharma Inc. will post 0.42 earnings per share for the current year.

Astellas Pharma Company Profile

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).